Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
That’s compared with HIV-negative men.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.
Increases may be designed to push patients to the company’s newer regimens.
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.
We now have four single tablet regimens.
Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.
It is more easily absorbed into white blood cells meaning you can take a lower dose.
Janssen and Gilead Sciences have announced amendments to ongoing collaborations to develop single-tablet regimens to treat HIV.
One of the most important drugs in the HIV arsenal is getting a tune-up.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.